Alentis Therapeutics
PrivateLast Round
Series D
Nov 12, 2024
Est. Valuation
$2B
Total Funding Raised
$365.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Alentis Therapeutics is a biotechnology company that develops innovative treatments for cancer and fibrotic diseases by targeting Claudin-1.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alentis Therapeutics Comparables
Compare Alentis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TORL BioTherapeutics | 78% | |
| Adcendo | 74% | |
| Sotio | 72% |
Alentis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 12, 2024 | ||||
| Series C | Apr 13, 2023 | ||||
| Series B | Jun 15, 2021 | ||||
| Series A | Apr 30, 2019 |
Key People
Founding team and executive leadership
Alentis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series D |
| Avego Management | Series D |
| BioMedPartners | Series A, Series B |
| RA Capital Management | Series D, Series C |
| Heartland Healthcare Capital | Series D |
| Morningside Ventures | Series B |
| OrbiMed | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 35% MoM, reaching 5.3K.
- Jun 18, 2026
Monthly visitors grew 164% MoM, reaching 6.4K.
Alentis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Alentis Therapeutics's valuation, stock price, and market status.
Is Alentis Therapeutics a public or private company?
Alentis Therapeutics is a private company.
What is the current stock price of Alentis Therapeutics?
Alentis Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Alentis Therapeutics worth (valuation)?
Alentis Therapeutics's valuation is estimated at $2.0B based on funding round data.
Can I buy Alentis Therapeutics stock?
Alentis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Alentis Therapeutics's last funding round?
Alentis Therapeutics's most recent funding round was Series D on June 15, 2021.
Who are the main investors in Alentis Therapeutics?
Key investors in Alentis Therapeutics include BioMedPartners, RA Capital Management, Morningside Ventures, OrbiMed, Novo Holdings.
Will Alentis Therapeutics IPO soon?
No public IPO plans have been announced for Alentis Therapeutics.
How can I track Alentis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Alentis Therapeutics's secondary market activity and sign up for updates.